** Drug developer enGene Holdings' ENGN.O shares rise 7.2% to $6.24

** H.C. Wainwright starts coverage with "buy" rating and PT of $25 — a ~4x upside to Friday's close

** Brokerage says ENGN's lead drug, detalimogene, can be administered safer and simpler than other gene therapies

** ENGN reported in September that the drug had a complete response rate at any time of 71% in patients with high-risk non-muscle invasive bladder cancer

** Brokerage says this is in-line with treatments from CG Oncology CGON.O and Johnson & Johnson JNJ.N

** Complete response rate is the percentage of patients in a clinical trial whose cancer completely disappears after treatment.

** Brokerage says investors should "consider the holistic risk/reward profiles of treatments" rather than focusing solely on the metric

** Expects FDA approval for ENGN's drug by 2027 and sales of $868 mln by 2034

** All ten brokerages rate stock "buy" or higher; median PT is $30 - LSEG

** As of last close, stock has fallen 36.8% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))